Liu Zeyu, Li Ming, Zhao Ziyi, Liu Aina, Sun Ping
Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Department of Hand and Foot, Microsurgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Oncol. 2024 Oct 3;14:1439984. doi: 10.3389/fonc.2024.1439984. eCollection 2024.
The anti-angiogenic agent anlotinib offers a new treatment option for triple-negative breast cancer (TNBC) patients with brain metastases. This study aimed to evaluate the efficacy and safety of anlotinib in the treatment of TNBC patients with brain metastases.
Between October 2019 and April 2024, 29 TNBC patients with brain metastases who had failed prior therapy and were treated with anlotinib were retrospectively analyzed. The primary endpoint was central nervous system (CNS) progression-free survival (PFS), and secondary endpoints included overall survival (OS), intracranial disease control rate (iDCR), intracranial objective response rate (iORR), and safety.
The median CNS PFS of 29 patients was 7.2 months (95% confidence interval [CI], 3.5-10.9 months), and the median OS was 10.2 months (95% CI, 5.6-14.8 months). The iORR and iDCR were 31.0% and 86.2%, respectively. Five patients (17.2%) experienced grade 3-4 adverse events (AEs), with bone marrow suppression (2/29, 6.9%) being the most common. Most AEs were clinically manageable, and no treatment-related death was observed.
Anlotinib demonstrated encouraging efficacy and manageable toxicity in the treatment of TNBC patients with brain metastases who had failed standard treatment.
抗血管生成药物安罗替尼为三阴性乳腺癌（TNBC）脑转移患者提供了一种新的治疗选择。本研究旨在评估安罗替尼治疗TNBC脑转移患者的疗效和安全性。
回顾性分析2019年10月至2024年4月期间29例先前治疗失败且接受安罗替尼治疗的TNBC脑转移患者。主要终点为中枢神经系统（CNS）无进展生存期（PFS），次要终点包括总生存期（OS）、颅内疾病控制率（iDCR）、颅内客观缓解率（iORR）和安全性。
29例患者的中位CNS PFS为7.2个月（95%置信区间[CI]，3.5 - 10.9个月），中位OS为10.2个月（95% CI，5.6 - 14.8个月）。iORR和iDCR分别为31.0%和86.2%。5例患者（17.2%）发生3 - 4级不良事件（AE），其中骨髓抑制最为常见（2/29，6.9%）。大多数AE在临床上可控制，未观察到与治疗相关的死亡。
对于标准治疗失败的TNBC脑转移患者，安罗替尼在治疗中显示出令人鼓舞的疗效和可管理的毒性。
